Jingyuan Wang

Jingyuan Wang is the Chairman of Hongmei Technology and Deputy General Manager of Zhongshan Xiangshang Investment Management. With a professional background spanning law, investment and corporate governance, his work focuses on healthcare investment, private equity, asset restructuring and strategic capital operations. His experience covers corporate listings, cross-border M&A, equity investment and governance restructuring. By combining legal expertise with an investment and industrial perspective, Jingyuan works closely with companies on capital strategy, transaction execution and long-term business development. Through Hongmei Technology, his work has further extended into biotechnology and sustainable manufacturing. The company is advancing a large-scale non-grain carbon-source synthetic biology manufacturing project, combining non-food feedstocks, next-generation strains and AI-enabled enzyme systems to improve resource efficiency and industrial-scale biomanufacturing capabilities. The project also brings together themes such as green manufacturing, supply-chain resilience and more efficient use of biological resources, creating a natural connection between industrial development and ESG-oriented investment. Across investment and corporate management, Jingyuan places particular emphasis on governance quality, responsible capital allocation and long-term value creation, with a focus on building stronger links between capital, technology and sustainable industrial development.

王靖远先生现任红莓科技公司董事长、中山香商投资管理有限公司副总经理，拥有法律、投资及企业治理等多维度专业背景，长期参与大健康产业投资、私募股权投资、资产重整及战略资本运作。 他的实务经验覆盖企业上市、跨境并购、股权投资及治理重组等多个领域，并善于将法律判断、资本运作与产业视角结合，为企业提供从交易执行、资本规划到长期发展的综合支持。 通过红莓科技，其产业实践进一步延伸至合成生物与绿色制造领域。公司目前正推进万吨级非粮碳源合成生物制造项目，通过非粮原料、第三代菌种及 AI 酶系等技术路径，提升生物制造的资源利用效率与规模化生产能力。项目同时涉及绿色制造、供应链韧性及生物资源高效利用等方向，使其产业投资实践与 ESG 所关注的可持续产业发展形成较自然的结合。 在投资与企业管理实践中，王靖远先生长期关注公司治理、资本配置效率与长期价值创造，并持续推动资本、科技与可持续产业发展之间的连接。